Effects of combined treatment with mephedrone and methamphetamine or 3,4-methylenedioxymethamphetamine on serotonin nerve endings of the hippocampus

Mariana Angoa-Pérez, Michael J. Kane, Nieves Herrera-Mundo, Dina M. Francescutti, Donald M. Kuhn

Department of Psychiatry & Behavioral Neurosciences, Wayne State University School of Medicine, Detroit, MI 48201, USA
Research & Development Service, John D. Dingell VA Medical Center, Detroit, MI 48201, USA

Abstract

Aims: Mephedrone is a stimulant drug of abuse with close structural and mechanistic similarities to methamphetamine and 3,4-methylenedioxymethamphetamine (MDMA). Although mephedrone does not damage dopamine nerve endings it increases the neurotoxicity of amphetamine, methamphetamine and MDMA. The effects of mephedrone on serotonin (5HT) nerve endings are not fully understood, with some investigators reporting damage while others conclude it does not. Presently, we investigate if mephedrone given alone or with methamphetamine or MDMA damages 5HT nerve endings of the hippocampus.

Main methods: The status of 5HT nerve endings in the hippocampus of female C57BL mice was assessed through measures of 5HT by HPLC and by immunoblot analysis of serotonin transporter (SERT) and tryptophan hydroxylase 2 (TPH2), selective markers of 5HT nerve endings. Astrocystosis was assessed through measures of glial fibrillary acidic protein (GFAP) (immunoblotting) and microglial activation was determined by histochemical staining with Isolectin B4.

Key findings: Mephedrone alone did not cause persistent reductions in the levels of 5HT, SERT or TPH2. Methamphetamine and MDMA alone caused mild reductions in 5HT but did not change SERT and TPH2 levels. Combined treatment with mephedrone and methamphetamine or MDMA did not change the status of 5HT nerve endings to an extent that was different from either drug alone.

Significance: Mephedrone does not cause toxicity to 5HT nerve endings of the hippocampus. When co-administered with methamphetamine or MDMA, drugs that are often co-abused with mephedrone by humans, toxicity is not increased as is the case for dopamine nerve endings when these drugs are taken together.

Published by Elsevier Inc.

Introduction

Abuse of illicit “bath salts” compounds continues to rise and now represents a significant public health crisis. One psychoactive ingredient of “bath salts” is mephedrone (4-methylmethcathinone). From a chemical perspective, mephedrone is a cathinone derivative and structural analog of methamphetamine and 3,4-methylenedioxymethamphetamine (MDMA). Other psychoactive ingredients of “bath salts” include methylene, butylone and 3, 4-methylenedioxypropylvlarone (MDPV). As abuse of j-ketoamphetamines continues to rise, the list of their adverse effects has grown to include cardiovascular complications, agitation, insomnia, psychosis and depression (Prosser and Nelson, 2012; Schifano et al., 2011; Wood and Dargan, 2012). Mephedrone is also being used increasingly to supplement more established club drugs such as MDMA and cocaine (Moore et al., 2013). Mephedrone has many of the same effects on the central nervous system as methamphetamine and MDMA. For example, it interacts with the monoamine plasma membrane transporters for dopamine (DA), serotonin (5HT) and norepinephrine (Baumann et al., 2012; Cozzi et al., 1999; Hadlock et al., 2011; Lopez-Arnau et al., 2012; Martinez-Clemente et al., 2012; Nagai et al., 2007; Simmler et al., 2013; Sogawa et al., 2011), blocks uptake of DA, 5HT and norepinephrine (Cozzi et al., 1999; Hadlock et al., 2011; Lopez-Arnau et al., 2012; Martinez-Clemente et al., 2012; Simmler et al., 2013) and stimulates release of these neurotransmitters (Baumann et al., 2012; Hadlock et al., 2011; Kehr et al., 2011) via its ability to serve as a transporter substrate (Baumann et al., 2012; Eshleman et al., 2013; Nagai et al., 2007). Mephedrone increases locomotor activity (Angoa-Pérez et al., 2012; Baumann et al., 2012; Marusich et al., 2012; Morby et al., 2012; Shortall et al., 2013), causes hyperthermia (Angoa-Pérez et al., 2013, 2012; Baumann et al., 2012; Hadlock et al., 2011) and provokes a Fos expression pattern in brain that closely resembles those of methamphetamine and MDMA (Motley et al., 2012a). The simultaneous stimulation of DA release and inhibition of its uptake, along with increases in body temperature and locomotor

Keywords:
Bath salts
Serotonin
Methamphetamine
MDMA
Mephedrone
Neurotoxicity

Article history:
Received 14 May 2013
Accepted 11 July 2013

Contents lists available at ScienceDirect
Life Sciences
dojournal homepage: www.elsevier.com/locate/lifescie

0024-3205/$ – see front matter. Published by Elsevier Inc.
http://dx.doi.org/10.1016/j.lfs.2013.07.015
activity mirror the critical elements underlying the neurotoxicity associated with methamphetamine (Cadet et al., 2007; Fleckenstein et al., 2007; Kuhn et al., 2008; Yamamoto and Bankson, 2005).

In view of the close structural and mechanistic overlap of mephedrone with methamphetamine and MDMA, it was predicted that mephedrone would cause toxicity to DA nerve endings. However, a number of studies have established that this drug does not cause persistent reductions in function of the DA neuronal system (Angoa-Pérez et al., 2012; Baumann et al., 2012; den Hollander et al., 2013; Hadlock et al., 2011; Motbey et al., 2012b; Shortall et al., 2013). The issue of whether mephedrone damages 5HT nerve endings remains unsettled as one study documented possible neurotoxic effects (Hadlock et al., 2011) while others have been negative in this regard (Baumann et al., 2012; den Hollander et al., 2013; Motbey et al., 2012b; Shortall et al., 2013). The present studies were carried out to determine if mephedrone alone or combined with methamphetamine or MDMA would unmask a neurotoxic effect on 5HT nerve endings.

Materials and methods

Drugs and reagents

Mephedrone hydrochloride and 3,4-methylenedioxymethamphetamine (MDMA) hydrochloride were obtained from the NIDA Research Resources Drug Supply Program. (+) Methamphetamine hydrochloride, Isolectin B4 (ILB4), pentobarbital, 5HT, 5-hydroxyindole acetic acid (5HIAA), and all buffers and HPLC reagents were purchased from Sigma-Aldrich (St. Louis, MO, USA). Bicinchoninic acid protein assay kits were obtained from Pierce (Rockford, IL, USA). Polyclonal antibodies against SERT were purchased from Santa Cruz Biotechnology (Dallas, TX, USA) and antibodies against GFAP were obtained from Neomarkers (Fremont, CA, USA). Polyclonal antibodies against TPH2 were prepared and used as previously described (Sakowski et al., 2006). HRP-conjugated anti-IgG secondary antibodies were provided by Jackson ImmunoResearch Laboratories, Inc. (West Grove, PA, USA).

Animals

Female C57BL/6 mice (Harlan, Indianapolis, IN, USA) weighing 20–25 g at the time of experimentation were housed 5 per cage in large shoe-box cages in a light- (12 h light/dark) and temperature-controlled room. Female mice were used because they are known to be very sensitive to neuronal damage by the neurotoxic amphetamines and to maintain consistency with our previous studies of methamphetamine neurotoxicity (Thomas et al., 2008, 2009, 2010). Mice had free access to food and water. The Institutional Care and Use Committee of Wayne State University approved the animal care and experimental procedures. All procedures were also in compliance with the NIH Guide for the Care and Use of Laboratory Animals.

Pharmacological procedures

Mice were treated with mephedrone using a binge-like regimen comprised of 4 injections of 20 mg/kg with a 2 h interval between each injection. This binge treatment regimen, when used to inject substituted amphetamines and cathinone derivatives, results in extensive DA nerve ending damage. The doses of mephedrone used presently were previously shown to be non-toxic to DA nerve endings (Angoa-Pérez et al., 2013, 2012). Mice were treated with methamphetamine (4X 5 mg/kg) or MDMA (4X 20 mg/kg) alone or in combination with mephedrone. When treated with two drugs, mice received a mephedrone injection 30 min prior to each of the 4 injections of methamphetamine or MDMA. Controls received injections of physiological saline on the same schedule used for mephedrone alone or in combination with other amphetamines. All injections were given via the i.p. route. Mice were sacrificed 2 days after the last drug treatment when amphetamine-associated neurotoxicity has reached maximum.

Determination of hippocampal 5HT and 5HIAA content

Hippocampus was dissected bilaterally from the brain after treatment and stored at −80 °C. Frozen tissues were weighed and sonicated in 10 volumes of 0.16 N perchloric acid at 4 °C. Insoluble protein was removed by centrifugation and 5HT and 5HIAA were determined by HPLC with electrochemical detection as previously described (Thomas et al., 2010).

Determination of SERT and TPH2 protein levels by immunoblotting

The effects of drug treatments on hippocampal SERT and TPH2 were determined by immunoblotting as an index of toxicity to 5HT nerve endings as previously reported (Thomas et al., 2010). Mice were sacrificed by decapsulation after treatment and hippocampus was dissected bilaterally. Tissue was stored at −80 °C. Frozen tissue was disrupted by sonication in 1% SDS at 95 °C and insoluble material was sedimented by centrifugation. Protein was determined by the bicinchorinic acid method and equal amounts of protein (70 µg/lane) were resolved by SDS-polyacrylamide gel electrophoresis and then electroblotted to nitrocellulose. Blots were blocked in Tris buffered saline containing Tween 20 (0.1% v/v) and 5% non-fat dry milk for 2 h at room temperature. Primary antibodies against SERT (1:250) or TPH2 (1:200) were added to blots and allowed to incubate for 16 h at 4 °C. Blots were washed 3X in Tris-buffered saline to remove unreacted antibodies and then incubated with HRP-conjugated anti-IgG secondary antibody (1:4000) for 1 h at room temperature. Immunoreactive bands were visualized by enhanced chemiluminescence and the relative densities of SERT- and TPH2-reactive bands were determined by imaging with a Kodak Image Station (Carestream Molecular Systems, Rochester, NY, USA) and quantified using ImageJ software (NIH).

Assessment of hippocampal gliosis

The effects of drug treatments on hippocampal astrocytosis were determined by immunoblotting for GFAP (1:2000) as described above for SERT and TPH2 and microglial activation was assessed by histochemical staining with ILB4 as previously reported (Thomas et al., 2004a, 2004b).

Data analysis

The effects of drug treatments on hippocampal 5HT and 5HIAA content, expression levels of SERT and TPH2 and gliosis were tested for significance by one-way ANOVA followed by Tukey’s multiple comparison test. Differences were considered statistically significant if p < 0.05. All statistical analyses were carried out using GraphPad Prism version 5.02 for Windows (GraphPad Software, San Diego, CA, USA, www.graphpad.com).

Results

Effects of mephedrone and methamphetamine on 5HT nerve endings

Mephedrone (20 mg/kg) was administered 30 min before each injection of methamphetamine (4X 5 mg/kg) and the effects are presented in Fig. 1A. The main effect of drug treatment on 5HT levels was significant (F3,30 = 5.02, p = 0.006) but neither mephedrone nor methamphetamine alone changed hippocampal 5HT levels. Combined treatment with mephedrone + methamphetamine did lower 5HT levels slightly (−20%) but significantly by comparison with controls (p < 0.05) and mephedrone alone (p < 0.001). The main effect of drug treatment on 5HIAA levels was also significant (F3,14 = 18.56,
Effects of mephedrone and MDMA on 5HT nerve endings

Mephedrone (20 mg/kg) was administered 30 min before each injection of MDMA (4X 20 mg/kg) and the effects are presented in Fig. 3A. The main effect of drug treatment on 5HT levels was significant (F3,17 = 22.52, p < 0.0001). It can be seen that mephedrone did not alter hippocampal 5HT while MDMA significantly reduced 5HT levels by comparison to control (p < 0.001) and mephedrone alone (p < 0.0001). Combined treatment with mephedrone + MDMA also significantly reduced 5HT levels by comparison with controls (p < 0.0001) and mephedrone alone (p < 0.0001), but MDMA + mephedrone did not differ significantly from MDMA alone. None of these treatments changed hippocampal 5HIAA levels (Fig. 3B). Likewise, none of these drug treatments altered the levels of SERT (Fig. 4A) or TPH2 (Fig. 4B) by comparison with controls.

Effects of mephedrone in combination with methamphetamine or MDMA on hippocampal gliosis

We have shown previously that both methamphetamine and MDMA cause microglial activation in striatum (Thomas et al., 2004a). Therefore, hippocampus was examined for evidence of astrogliosis via measures of GFAP and for microglial activation via histochemical staining with ILB4. Results in Fig. 5 show that mephedrone, methamphetamine or MDMA alone did not change GFAP levels in hippocampus. Similarly, combined treatment with mephedrone + methamphetamine or mephedrone + MDMA did not alter hippocampal levels of GFAP. The effects of these same drug treatments on microglial status were assessed and results in Fig. 6 show that none of the drugs given alone or in combination caused microglial activation in hippocampus.

Discussion

Mephedrone has become one of the most common drug of abuse following cannabis, MDMA and cocaine (Morris, 2010; Winstock et al., 2011b) and its use will likely surpass that of MDMA as the purity of this latter drug continues to fall (Brunt et al., 2011; Tanner-Smith, 2011b).
Mephedrone induces stronger feelings of craving in humans by comparison to MDMA (Brunet et al., 2011) and users who snort mephedrone rate it as more addictive than cocaine (Winstock et al., 2011b). The strong abuse potential of mephedrone has also been confirmed by emerging preclinical studies showing its ability to cause locomotor sensitization (Lisek et al., 2012; Shortall et al., 2013), establish a conditioned place preference (Lisek et al., 2012) and sustain intravenous self-administration (Hadlock et al., 2011).

Considering the close structural and mechanistic overlaps between mephedrone and the neurotoxic amphetamines, it was surprising to find that mephedrone does not cause damage to DA nerve endings of the striatum in mice (Angoa-Pérez et al., 2012; Baumann et al., 2012; den Hollander et al., 2013; Hadlock et al., 2011; Motbey et al., 2012b; Shortall et al., 2013). On the other hand, given the manner in which it interacts with DA and 5HT transporters, it has been predicted that mephedrone would protect against methamphetamine- or MDMA-induced neurotoxicity. This latter possibility has been ruled out by studies showing that mephedrone enhances damage to DA nerve endings caused by methamphetamine, MDMA and amphetamine (Angoa-Pérez et al., 2012). Based on common patterns of abuse of mephedrone and other “bath salts” ingredients (i.e., consumed in a binge-like fashion and often taken with other drugs such as cannabis and the amphetamine psychostimulants (Fass et al., 2012; Kelly, 2011; Moore et al., 2013; Schifano et al., 2011; Torrance and Cooper, 2010; Winstock et al., 2011a)) it becomes important to determine if mephedrone damages 5HT nerve endings and if it can interact with methamphetamine and MDMA to enhance their toxicity.

In the present study, we found that mephedrone alone did not cause damage to hippocampal 5HT nerve endings. The levels of 5HT (and its main metabolite 5HIAA), SERT and TPH2 were unchanged by a binge-treatment regimen using relatively high doses of mephedrone. This result is in good agreement with other recent studies showing that mephedrone did not cause persistent depletion of 5HT (Baumann et al., 2012; den Hollander et al., 2013; Motbey et al., 2012b; Shortall et al., 2013). The one study reporting that mephedrone caused 5HT deficits (Hadlock et al., 2011) used similar experimental subjects and treatment conditions as employed by the studies referenced above, so the reason for this discrepancy is not clear. By extending these studies to a poly-drug use paradigm, it was also observed that mephedrone did not enhance the effects of either methamphetamine or MDMA on hippocampal 5HT neuronal markers. Although methamphetamine did cause a mild reduction in 5HIAA levels, this effect was not modified by mephedrone. MDMA caused a significant reduction in hippocampal 5HT levels and this effect was likewise unmodified by mephedrone. Mephedrone alone or in combination with methamphetamine or MDMA did not alter the levels of SERT or TPH2, two highly specific protein markers for 5HT nerve endings.

Increased expression of GFAP is an index of astroglial astrogliosis and has been used extensively as a marker of amphetamine-induced CNS damage (O’Callaghan and Miller, 1993; 1994). It has also been shown that microglial activation is a pharmacologically specific marker for the neurotoxic amphetamines (Bowyer et al., 1994; LaVoie et al., 2004; Thomas et al., 2004a). Gliosis was assessed in hippocampus after mephedrone injections and it was observed that the levels of GFAP were not changed from control, and microglial activation was not seen. Neither methamphetamine nor MDMA caused gliosis in hippocampus when given alone and combined treatment with mephedrone + methamphetamine or mephedrone + MDMA likewise did not change the levels of GFAP or cause microglial activation. Both methamphetamine and MDMA cause extensive astrogliosis (O’Callaghan and Miller, 1993; 1994) and microglial activation in striatum (Bowyer et al., 1994; LaVoie et al., 2004; Thomas et al., 2004a, 2009; Thomas and Kuhn, 2005; Thomas et al., 2004b) in a manner that is associated with amphetamine-induced neurotoxicity to DA nerve endings in this brain region. Although our previous research on the effects of mephedrone on the DA neuronal system did not report data on striatal gliosis (Angoa-Pérez et al., 2013, 2012), we have not yet observed any evidence of gliosis in striatum (unpublished observations).

Taken together, the results of the present experiments suggest that mephedrone does not cause damage to 5HT nerve endings of the hippocampus. Methamphetamine and MDMA alone lead to minor disruptions in 5HT neurochemistry (i.e., reduced turnover) but these do not appear to rise to the level of neurotoxicity because stable protein markers such as SERT and TPH2 were not altered and gliosis was not observed. We purposefully used high doses of methamphetamine and MDMA because their effects on 5HT nerve endings outside of the striatum are somewhat mild and possibly non-toxic (Baumann et al., 2007). Nevertheless, when mephedrone was administered with either methamphetamine or MDMA, an enhancement of any drug effect on 5HT, SERT or TPH2 levels was not observed. Likewise, these combined drug treatments did not result in hippocampal gliosis. The question of whether MDMA damages the 5HT neuronal system remains a contested issue (Baumann et al., 2007; McLane et al., 2011; Wang et al., 2005,

![Fig. 4. Effects of mephedrone and MDMA on hippocampal levels of SERT and TPH2](image1.png)

Mice were treated with mephedrone (Meph; 20 mg/kg) 30 min prior to each of the 4 injections of MDMA (20 mg/kg) and sacrificed 2 days later for determination of hippocampal levels of SERT (A) or TPH2 (B) by immunoblotting. Blots were quantified using ImageJ and data are mean ± SEM for 5–7 mice per group.

**Fig. 5. Effects of mephedrone, methamphetamine and MDMA on hippocampal GFAP.** Mice were treated with mephedrone (Meph; 20 mg/kg), methamphetamine (Meth; 5 mg/kg) or MDMA (20 mg/kg), or the combinations of mephedrone + methamphetamine or MDMA. When given in combination, mephedrone was given 30 min prior to each of the 4 injections of methamphetamine or MDMA. Mice were sacrificed 2 days after treatment for determination of hippocampal GFAP by immunoblotting. Blots were quantified using ImageJ. Data are mean ± SEM for 5–7 mice in each group.
2004; Xie et al., 2006). Mephedrone, on the other hand, does not damage DA or 5HT nerve endings despite being a chemical congener of the neurotoxins methamphetamine and MDMA. Our conclusion that mephedrone has low neurotoxic potential within the 5HT neuronal system should be tempered somewhat in view of the fact that mice are not as sensitive to the 5HT-damaging effects of MDMA as rats and other species (Baumann et al., 2007; Colado et al., 2004). This could lead to an underestimation of mephedrone-induced toxicity to 5HT nerve endings. Furthermore, brain regions in addition to the hippocampus should be studied for their response to mephedrone to determine if this drug exerts toxic effects on 5HT nerve endings that are brain-region specific. We have shown previously that mephedrone does not prevent the hyperthermia caused by methamphetamine or MDMA (Angoa-Pérez et al., 2012, 2013), ruling out the possibility that its low toxicity is related to prevention of amphetamine-induced increases in core temperature. Future research on methamphetamine- and MDMA-induced neurotoxicity should focus on the minor structural differences with mephedrone that renders the latter drug non-neurotoxic.

**Conclusion**

Mephedrone is a powerful psychostimulant with high abuse potential. Mephedrone shares many chemical and mechanistic properties with the neurotoxic amphetamines but does not cause neurotoxic effects on the DA neuronal system. The present work confirms other reports that mephedrone does not appear to cause persistent deficits in 5HT nerve ending function. The ability of mephedrone to accentuate the toxic effects of methamphetamine and MDMA on DA nerve endings does not extend to 5HT nerve endings of the hippocampus. It will be interesting to determine if other psychoactive ingredients of “bath salts” such as methylone, butylone and MDPV are also devoid of neurotoxic effects.

**Conflict of interest statement**

All the authors declared no competing interests.

**Acknowledgements**

This work was supported by grants from the National Institute on Drug Abuse and the Department of Veterans Affairs.


McLane MW, McCann U, Ricaurte G. Identifying the serotonin transporter signal in Western blot studies of the neurotoxic potential of MDMA and related drugs. Synapse 2011;65:1368–72.


Tanner-Smith EE. Pharmacological content of tablets sold as “ecstasy”: results from an online testing service. Drug Alcohol Depend 2006;83:247–54.


